Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported. METHODS: This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Provencio, Mariano, Serna-Blasco, Roberto, Nadal, Ernest, Insa, Amelia, García-Campelo, M. Rosario, Casal Rubio, Joaquín, Dómine, Manuel, Majem, Margarita, Rodríguez-Abreu, Delvys, Martínez-Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Pereira, Eva, Royuela, Ana, Calvo, Virginia, Martín-López, Javier, García-García, Francisco, Casarrubios, Marta, Franco, Fernando, Sánchez-Herrero, Estela, Massuti, Bartomeu, Cruz-Bermúdez, Alberto, Romero, Atocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426809/
https://www.ncbi.nlm.nih.gov/pubmed/35576508
http://dx.doi.org/10.1200/JCO.21.02660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426809/
https://www.ncbi.nlm.nih.gov/pubmed/35576508
http://dx.doi.org/10.1200/JCO.21.02660

Ejemplares similares